Artiva Biotherapeutics (NASDAQ:ARTV) Director Ra Capital Management, L.P. Purchases 20,824 Shares

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. acquired 20,824 shares of the business’s stock in a transaction on Wednesday, July 29th. The stock was acquired at an average price of $9.99 per share, for a total transaction of $208,031.76. Following the acquisition, the director owned 17,304,626 shares of the company’s stock, valued at approximately $172,873,213.74. This trade represents a 0.12% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Friday, July 31st, Ra Capital Management, L.P. purchased 24,944 shares of Artiva Biotherapeutics stock. The stock was bought at an average cost of $9.93 per share, for a total transaction of $247,693.92.
• On Friday, July 24th, Ra Capital Management, L.P. purchased 41,319 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $9.99 per share, for a total transaction of $412,776.81.
• On Thursday, July 23rd, Ra Capital Management, L.P. purchased 59,880 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $9.96 per share, for a total transaction of $596,404.80.
• On Wednesday, July 22nd, Ra Capital Management, L.P. acquired 84,124 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $9.93 per share, with a total value of $835,351.32.
• On Tuesday, July 21st, Ra Capital Management, L.P. acquired 120,582 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $9.55 per share, with a total value of $1,151,558.10.
• On Friday, July 10th, Ra Capital Management, L.P. acquired 15,102 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $8.97 per share, with a total value of $135,464.94.
• On Monday, July 13th, Ra Capital Management, L.P. bought 6,552 shares of Artiva Biotherapeutics stock. The stock was bought at an average cost of $8.94 per share, for a total transaction of $58,574.88.
• On Friday, June 26th, Ra Capital Management, L.P. bought 1,876 shares of Artiva Biotherapeutics stock. The stock was bought at an average cost of $8.98 per share, for a total transaction of $16,846.48.
• On Thursday, June 25th, Ra Capital Management, L.P. bought 31,000 shares of Artiva Biotherapeutics stock. The stock was bought at an average cost of $8.88 per share, for a total transaction of $275,280.00.
• On Tuesday, June 16th, Ra Capital Management, L.P. purchased 124,893 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $8.89 per share, with a total value of $1,110,298.77.

Artiva Biotherapeutics Price Performance

ARTV opened at $10.10 on Friday. The stock has a 50-day moving average price of $9.01 and a 200-day moving average price of $7.51. The firm has a market cap of $249.67 million, a PE ratio of -2.85 and a beta of 2.18. Artiva Biotherapeutics, Inc. has a 1 year low of $2.22 and a 1 year high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its quarterly earnings results on Friday, May 8th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). As a group, sell-side analysts anticipate that Artiva Biotherapeutics, Inc. will post -2.45 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on ARTV shares. HC Wainwright increased their price target on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a report on Friday, May 8th. Cantor Fitzgerald restated an “overweight” rating on shares of Artiva Biotherapeutics in a report on Tuesday, May 26th. Wall Street Zen cut Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, May 17th. Wedbush increased their target price on Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a research note on Monday, May 11th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Tuesday, July 21st. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Artiva Biotherapeutics currently has an average rating of “Moderate Buy” and an average target price of $39.00.

Hedge Funds Weigh In On Artiva Biotherapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Citadel Advisors LLC grew its holdings in shares of Artiva Biotherapeutics by 419.3% in the third quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock worth $2,291,000 after acquiring an additional 644,658 shares during the period. BNP Paribas Financial Markets increased its position in Artiva Biotherapeutics by 14,463.5% during the third quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock valued at $340,000 after acquiring an additional 117,733 shares during the last quarter. Marshall Wace LLP bought a new position in Artiva Biotherapeutics in the fourth quarter valued at about $341,000. Jane Street Group LLC bought a new position in Artiva Biotherapeutics in the second quarter valued at about $67,000. Finally, Landscape Capital Management L.L.C. bought a new position in Artiva Biotherapeutics in the third quarter valued at about $112,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.